Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results